Systemic collagen VII replacement therapy for advanced recessive dystrophic epidermolysis bullosa.

Abstract Recessive dystrophic epidermolysis bullosa (RDEB) is a genetic skin blistering disease associated with progressive multi-organ fibrosis. RDEB is caused by biallelic mutations in COL7A1 encoding the extracellular matrix protein collagen VII (C7), which is necessary for epidermal-dermal adherence. C7 is not simply a structural protein but also has multiple functions, including regulation of TGFβ bioavailability and the inhibition of skin scarring. Intravenous (IV) administration of recombinant C7 (rC7) rescues C7 deficient mice from neonatal lethality. However, the effect on established RDEB has not been determined. Here, we used small and large adult RDEB animal models to investigate the disease-modulating abilities of IV rC7 on established RDEB. In adult RDEB mice, rC7 accumulated at the basement membrane zone in multiple organs after single infusion. Fortnightly IV injections of rC7 for 7 weeks in adult RDEB reduced fibrosis of skin and eye. The fibrosis-delaying effect was associated with reduction of TGFβ signaling. IV-rC7 in adult RDEB dogs incorporated in the DEJ of skin and improved disease by promoting wound healing and reducing dermal-epidermal separation. In both species, IV C7 was well tolerated. These preclinical studies suggest that repeated IV administration of rC7 is an option for systemic treatment of established adult RDEB.